Catalyst Wire Dossier Catalyst Wire Dossier

Datopotamab Deruxtecan (Dato-DXd)

datopotamab deruxtecan · Daiichi Sankyo
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Datopotamab Deruxtecan (Dato-DXd), covering 2025-09-29 to 2026-03-19. Get the full timeline:

Most recent: Clinical Trial Update: Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2, Phase 3]

See pricing